中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.012 seconds)

    3,5-DIHYDROXY-2,4-CYCLOHEXADIENONES AND THEIR DERIVATIVES, DIETARY COMPOSITIONS AND FORTIFIED FOOD CONTAINING THEM AND THEIR USES
    3.
    发明申请
    3,5-DIHYDROXY-2,4-CYCLOHEXADIENONES AND THEIR DERIVATIVES, DIETARY COMPOSITIONS AND FORTIFIED FOOD CONTAINING THEM AND THEIR USES 审中-公开
    3,5-DIHYDROXY-2,4-CYCLOHEXADENENESES及其衍生物，膳食组合物和含有它们的食品及其用途

    公开(公告)号：WO2007134868A3

    公开(公告)日：2008-06-12

    申请号：PCT/EP2007004628

    申请日：2007-05-24

    Applicant: DSM IP ASSETS BV ,  DE SAIZIEU ANTOINE ,  GORALCZYK REGINA ,  FOWLER ANN ,  SCHUELER GOEDE

    Inventor： DE SAIZIEU ANTOINE ,  GORALCZYK REGINA ,  FOWLER ANN ,  SCHUELER GOEDE

    IPC: A23L1/30 ,  A23K1/16 ,  A23K1/18 ,  A61K31/00 ,  A61P25/24

    CPC classification number: A61K31/122 ,  A23K20/10 ,  A23K50/10 ,  A23K50/30 ,  A23K50/42 ,  A23K50/48 ,  A23K50/75 ,  A23L33/105

    Abstract: The present invention refers especially to 3,5-dihydroxy-2,4-cyclohexadienones of the general formula(I) wherein R 1 and R 2 are independently from each other C 1-6 -alkyl, C 2-6 -alkenyl or x-oxo-C x -alkyl with x being an integer from 1 to 6, preferably R 1 and R 2 are independently from each other C 2-6 -alkenyl or y-oxo-C y -alkyl with y being an integer from 2 to 5, and wherein R 3 and R 4 are independently from each other hydroxy, C 1-6 -alkyl, C 2-6 -alkenyl or x-oxo-C x -alkyl with x being an integer from 1 to 6, preferably R 3 and R 4 are independently from each other hydroxy or y-oxo-C y -alkyl with y being an integer from 2 to 5, for use as mood balancing agents and stress relievers, as well as to dietary compositions and fortified food/feed/beverages containing such 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I), and their uses.

    Abstract translation: 本发明特别涉及通式（I）的3,5-二羟基-2,4-环己二烯酮，其中R 1和R 2彼此独立地为C C 1-6 - 烷基，C 2-6 - 烯基或x-氧代-C≡C-烷基，其中x是1至 6，优选R 1和R 2彼此独立地为C 2-6 - 烯基或γ-氧代-Cy 其中y为2至5的整数，并且其中R 3和R 4彼此独立地为羟基，C 1〜 6个 - 烷基，C 2-6 - 烯基或x-氧代-C 0 - - - 烷基，x为1至6的整数， SO 3和R 4彼此独立地为羟基或γ-氧代-C 0 - 烷基，y为2至5的整数，对于 用作情绪平衡剂和应激缓解剂，以及含有这种一般的3,5-二羟基-2,4-环己二烯酮的饮食组合物和强化食品/饲料/饮料 公式（I）及其用途。

    MEDICAMENT FOR THE TREATMENT OF IMPAIRED GLUCOSE METABOLISM
    4.
    发明申请
    MEDICAMENT FOR THE TREATMENT OF IMPAIRED GLUCOSE METABOLISM 审中-公开
    用于治疗有害葡萄糖代谢的药物

    公开(公告)号：WO2006136423A3

    公开(公告)日：2007-03-01

    申请号：PCT/EP2006006038

    申请日：2006-06-23

    Applicant: DSM IP ASSETS BV ,  D ORAZIO DANIEL ,  DE SAIZIEU ANTOINE ,  SCHUELER GOEDE ,  WANG-SCHMIDT YING ,  WEHRLI CHRISTOF ,  WOLFRAM SWEN

    Inventor： D ORAZIO DANIEL ,  DE SAIZIEU ANTOINE ,  SCHUELER GOEDE ,  WANG-SCHMIDT YING ,  WEHRLI CHRISTOF ,  WOLFRAM SWEN

    IPC: A61K31/12 ,  A23L1/307

    CPC classification number: A61K31/12 ,  A23K20/111 ,  A23K50/20 ,  A23K50/40 ,  A23L33/10 ,  A23V2002/00 ,  A23V2200/328

    Abstract: The present invention relares to compounds of the formula (I) wherein R 3 is C 1-6 -alkyloxy, C 1-6 -acyloxy or aroyloxy; R 6 is hydrogen or C 1-6 -alkyloxy; R 7 is C 1-6 -alkyloxy, C 1-6 -acyloxy, aroyloxy or arylacyloxy; R 8 is hydrogen or C 1-6 -alkyloxy; or R 7 and R 8 form together a group O-L-O with L being (CR 1 R 2 ) n , with R 1 and R 2 being independently from each other hydrogen or C 1-5 -alkyl and n being an interger from 1 to 3; R 10 is hydrogen or N-C 1-4 -acyl, N- C 1-5 -alkyl-x-C x -alkyl with x being an interger from 1 to 5, for use as medicament for the treatment of a disorder connected to impaired glucose metabolism and impaired insulin action such as syndrome X and diabetes type 1,apd 2, especially for the treatment of (non-autoimmune) diabetes type 2. The invention also relates to food and pharmaceutical compositions containing these compounds.

    Abstract translation: 本发明涉及式（I）化合物，其中R 3是C 1-6 - 烷氧基，C 1-6 - 酰氧基 或芳酰基; R 6是氢或C 1-6 - 烷氧基; R 7是C 1-6 - 烷氧基，C 1-6 - 酰氧基，芳氧基或芳基酰氧基; R 8是氢或C 1-6 - 烷氧基; 或R 7和R 8形成在一起的基团OLO，其中L为（CR 1，R 2）2 其中R 1和R 2彼此独立地为氢或C 1-5烷基，n为 1到3的整数; R 10是氢或NC 1-4 - 酰基，N-C 1-5 - 烷基-XC

    NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION
    5.
    发明申请
    NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION 审中-公开
    防止和治疗与神经传导障碍有关的新药

    公开(公告)号：WO2006042441A3

    公开(公告)日：2006-07-13

    申请号：PCT/CH2005000621

    申请日：2005-10-21

    Applicant: DSM IP ASSETS BV ,  DE SAIZIEU ANTOINE ,  FOWLER ANN ,  GORALCZYK REGINA ,  MUSSLER BERND ,  SCHUELER GOEDE

    Inventor： DE SAIZIEU ANTOINE ,  FOWLER ANN ,  GORALCZYK REGINA ,  MUSSLER BERND ,  SCHUELER GOEDE

    IPC: A61K31/37

    CPC classification number: A61K31/37 ,  A23L2/39 ,  A23L7/126 ,  A23L33/105 ,  A23V2002/00 ,  A23V2250/21 ,  A23V2200/322

    Abstract: The present invention refers to coumarin ethers of the formula (I), wherein R 1 is H, OH or (E)-3-methyl-but-2-enyl, R 2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R 3 is H, R 1 and R 2 O together for the group -O-C(C(=CH 2 )CH 3 )H-CH 2 -O- or the group -C(H)=C(H)-C(CH 3 ) 2 -O- or R 2 O and R 3 together form the group -O-C(H)(C(CH 3 ) 2 (H)-O-C(O)CH 3 )-CH 2 -, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.

    Abstract translation: 本发明涉及式（I）的香豆素醚，其中R 1是H，OH或（E）-3-甲基 - 丁-2-烯基，R 2是氢， 选自甲基，3-（4,5-二氢-5,5-二甲基-4-呋喃酮-2-基）-2-（E / Z） - 丁烯基，（E / Z） -3,7-二甲基辛-2,6-二烯基，7-羟基-3,7-二甲基-2-辛烯-6-酮基和（E / Z，E / Z）-11-乙酰氧基-3 ，7,11,11-四甲基 - 十一碳-2,7-二烯-10-基 - ，R 3是H，R 1和R 2相同或不同， （C（= CH 2 ）CH 3 ）H-CH 2 -O-或 基团-C（H）= C（H）-C（CH 3）2 -O-或R 2 O和R 2， （H）-C（CH 3）2（H）-OC（O）CH 3（CH 3） ） - CH 2 - ，优选地用作药物，用作药物，特别是用于治疗和/或预防与神经传递受损相关的病症，以及饮食和药物组合物和 含有香豆素醚的植物提取物及其用途 。

    METHOD OF TREATMENT OR PREVENTION OF AGE-RELATED MACULAR DEGENERATION
    8.
    发明申请
    METHOD OF TREATMENT OR PREVENTION OF AGE-RELATED MACULAR DEGENERATION 审中-公开
    治疗或预防老年相关性变性的方法

    公开(公告)号：WO2007029008A2

    公开(公告)日：2007-03-15

    申请号：PCT/GB2006003331

    申请日：2006-09-08

    Applicant: DSM IP ASSETS BV ,  WRIGHT SIMON MARK ,  GORALCZYC REGINA ,  DE SAIZIEU ANTOINE ,  SCHALCH WOLGFANG ,  BENDIK IGOR

    Inventor： GORALCZYC REGINA ,  DE SAIZIEU ANTOINE ,  SCHALCH WOLGFANG ,  BENDIK IGOR

    CPC classification number: A61K33/34 ,  A61K31/047 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00

    Abstract: A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

    Abstract translation: 一种治疗和/或预防年龄相关性黄斑变性（AMD）的方法，其中在第一步骤中，对个体确定对AMD的治疗或易感性的需要，并且在第二步骤中，包含叶黄素和/ 或玉米黄质和/或某些抗氧化剂（或其混合物）适合该个体。 本发明还提供了确定待给予个体的物质的方法，该个体可能易患有年龄相关性黄斑变性（或年龄相关性黄斑变性相关病症），其包括：a）确定 个体对年龄相关性黄斑变性（通常在遗传上，通过检测SNP）; 和b）基于a）中确定的物质，鉴定能够预防或治疗该个体年龄相关性黄斑变性的物质。 该方法可以另外包括向个体提供（例如管理或通信）物质（或其身份）。

    NOVEL USE OF ORGANIC COMPOUNDS
    9.
    发明申请
    NOVEL USE OF ORGANIC COMPOUNDS 审中-公开
    有机化合物的新用途

    公开(公告)号：WO2006136423A2

    公开(公告)日：2006-12-28

    申请号：PCT/EP2006/006038

    申请日：2006-06-23

    Applicant: DSM IP ASSETS B.V. ,  D'ORAZIO, Daniel ,  DE SAIZIEU, Antoine ,  SCHUELER, Göde ,  WANG-SCHMIDT, Ying ,  WEHRLI, Christof ,  WOLFRAM, Swen

    Inventor： D'ORAZIO, Daniel ,  DE SAIZIEU, Antoine ,  SCHUELER, Göde ,  WANG-SCHMIDT, Ying ,  WEHRLI, Christof ,  WOLFRAM, Swen

    CPC classification number: A61K31/12 ,  A23K20/111 ,  A23K50/20 ,  A23K50/40 ,  A23L33/10 ,  A23V2002/00 ,  A23V2200/328

    Abstract: The present invention relates to compounds of the formula (I); wherein R 3 is C 1-6 -alkyloxy, C 1-6 -acyloxy or aroyloxy; R 6 is hydrogen or C 1-6 -alkyloxy; R 7 is C 1-6 -alkyloxy,C 1-6 -acyloxy, aroyloxy or arylacyloxy; R 8 is hydrogen or C 1-6 -alkyloxy; or R 7 and R 8 form together a group O-L-O with L being (CR 1 R 2 ) n, with R 1 and R 2 being independently from each other hydrogen or C 1-5 -alkyl and n being an integer from 1 to 3; R 10 is hydrogen or N-C 1-4 -acyl, N-C 1-5 -alkyl-x-C x -alkyl with x being an integer from 1 to 5, for use as medicament for the treatment of a disorder connected to impaired glucose metabolism and impaired insulin action such as syndrome X and diabetes type 1 and 2, especially for the treatment of (non-autoimmune) diabetes type 2. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of treating a disorder connected to impaired glucose metabolism and impaired insulin action in mammals including humans and to the compounds of the formula (I) themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the treatment of a disorder connected to impaired glucose metabolism and impaired insulin action.

    Abstract translation: 本发明涉及式（I）的化合物; 其中R 3是C 1-6 - 烷氧基，C 1-6 - 酰氧基或芳酰氧基; R 6是氢或C 1-6 - 烷氧基; R 7是C 1-6 - 烷氧基，C 1-6 - 酰氧基，芳氧基或芳基酰氧基; R 8是氢或C 1-6 - 烷氧基; 或R 7和R 8形成在一起的基团OLO，其中L为（CR 1，R 2）2 其中R 1，R 2和R 2彼此独立地为氢或C 1-5烷基，n为 1到3的整数; R 10是氢或NC 1-4 - 酰基，NC 1-5 - 烷基-XC x - 烷基，x为1至5的整数，用作治疗与葡萄糖代谢受损和胰岛素作用受损有关的病症的药物，例如综合征X和1型和2型糖尿病，特别是用于治疗（非自身免疫性 ）糖尿病2.本发明还涉及饮食组合物，例如（强化）食品，饮料，（强化）饲料，食品添加剂，饮料添加剂，饲料添加剂，临床营养，膳食补充剂，功能性食品，功能性饲料和营养品 和含有这些化合物的药物组合物，涉及治疗与包括人类在内的哺乳动物以及式（I）化合物本身的葡萄糖代谢受损和胰岛素作用受损相关的病症的方法。 本发明的另一个目的是使用这些化合物来制造用于治疗与糖代谢障碍和胰岛素作用受损有关的病症的组合物。

    LIGUSTILIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
    10.
    发明申请
    LIGUSTILIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM 审中-公开
    用于治疗中枢神经系统疾病的LIGESTILIDE衍生物

    公开(公告)号：WO2008017491A8

    公开(公告)日：2009-05-07

    申请号：PCT/EP2007007086

    申请日：2007-08-10

    Applicant: DSM IP ASSETS BV ,  DE SAIZIEU ANTOINE ,  GORALCZYK REGINA ,  SCHUELER GOEDE

    Inventor： DE SAIZIEU ANTOINE ,  GORALCZYK REGINA ,  SCHUELER GOEDE

    IPC: A61K31/343 ,  A61P25/22 ,  A61P25/24

    CPC classification number: A61K31/343

    Abstract: The present invention refers to compounds of the general formula (I) wherein R1 is hydrogen or hydroxy; R2 is butyl or butyryl if R1 is hydroxy, but R2 is butyl if R1 is hydrogen; or R1 and R2 taken together are 1-propylidene or 1-butylidene optionally substituted by hydroxy, methyl, or 3-(a,ß-dimethylacryloyloxy); the dotted line is an optional bond; X is an optionally substituted aliphatic C4- residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3 or X5 if the dotted line in formula (I) is absent; and X is Xl, X4 or X5 if the dotted line signifies a bond in formula (I) above; R3 and R4 are, independently from each other, hydrogen or hydroxy; and R5 is hydroxy or butyryl, for use in the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions containing such compounds, and their uses.

    Abstract translation: 本发明涉及通式（I）的化合物，其中R 1是氢或羟基; 如果R 1是羟基，则R 2是丁基或丁酰基，但如果R 1是氢，则R 2是丁基; 或R 1和R 2一起为1-羟基，甲基或3-（a，β-二甲基丙烯酰氧基）任意取代的1-亚丙基或1-亚丁基; 虚线是可选的键; X是选自X 1，X 2，X 3，X 4和X 5的任选取代的脂族C 4 - 残基; 其中如果式（I）中的虚线不存在，X是X 2，X 3或X 5; 如果虚线表示上述式（I）中的键，X为X 1，X 4或X 5; R 3和R 4彼此独立地为氢或羟基; 和R5是羟基或丁酰基，用于治疗与受损的神经传递相关的疾病，以及含有这些化合物的饮食和药物组合物及其用途。

Patent Agency Ranking